19 completed. 19 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 1 | 7 | Completed 7 |
Follow entinostat: new trials by email Literature Review of entinostat trials Research Report on entinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma Entinostat, Pembrolizumab - Melanoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 11 | 2019-03-22 | 2024-01-10 |
| Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye Pembrolizumab, Entinostat - Metastatic Uveal Melanoma | Phase 2 | Completed | Vastra Gotaland Region | 29 | 2018-02-21 | 2023-12-08 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat - Breast Neoplasms | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 144 | 2017-12-22 | 2025-11-10 |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Entinostat, Nivolumab - Metastatic Cholangiocarcinoma, Cholangiocarcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 44 | 2017-11-06 | 2025-05-28 |
| Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer Entinostat, Entinostat(Placebo), Exemestane - Advanced or Recurrent Breast Cancer | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 133 | 2017-09-22 | 2022-06-21 |
| Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer entinostat, avelumab, Placebo - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 1 / Phase 2 | Completed | Syndax Pharmaceuticals | 140 | 2016-12-19 | 2024-01-10 |
| Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In Entinostat, Atezolizumab, Placebo - Breast Cancer | Phase 1 / Phase 2 | Completed | Syndax Pharmaceuticals | 89 | 2016-05-01 | 2024-12-04 |
| Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) entinostat, pembrolizumab - Non-Small Cell Lung Cancer, Melanoma | Phase 1 / Phase 2 | Completed | Syndax Pharmaceuticals | 191 | 2015-08-26 | 2025-03-20 |
| Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. Azacitidine, Entinostat, Nivolumab - Non-Small Cell Lung Cancer, Epigenetic Therapy | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 143 | 2013-11-06 | 2024-05-03 |
| Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer Azacitidine, Entinostat, Laboratory Biomarker Analysis - Male Breast Carcinoma, Recurrent Breast Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 58 | 2011-08-15 | 2025-04-27 |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer entinostat, azacitidine, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2010-04-01 | 2014-08-01 |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing Entinostat, Aromatase Inhibitor (AI) Therapy - ER+ Breast Cancer | Phase 2 | Completed | Syndax Pharmaceuticals | 27 | 2008-10-01 | 2022-06-30 |
| Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer entinostat, exemestane, Placebo - Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 2 | Completed | Syndax Pharmaceuticals | 130 | 2008-06-13 | 2022-05-11 |
| Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC Entinostat, Placebo, Erlotinib - Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Completed | Syndax Pharmaceuticals | 141 | 2008-01-08 | 2022-08-22 |
| MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia entinostat, sargramostim - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2007-04-01 | 2017-07-18 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Azacitidine, Entinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 197 | 2006-08-01 | 2017-02-02 |
| Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2 - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 94 | 2006-08-01 | 2019-05-09 |
| Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) - Melanoma | Phase 2 | Completed | Bayer | 28 | 2004-12-01 | 2015-12-14 |
Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Melanoma (3) · Colonic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Anus Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Cholangiocarcinoma (1) · Congenital Abnormalities (1) · Fallopian Tube Neoplasms (1)
National Cancer Institute (NCI) (6) · Syndax Pharmaceuticals (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Bayer (1) · Hoffmann-La Roche (1) · Kyowa Kirin Co., Ltd. (1) · UNC Lineberger Comprehensive Cancer Center (1) · Vastra Gotaland Region (1)
United States (15) · Canada (1) · Czechia (1) · Georgia (1) · Hungary (1) · Ireland (1) · Israel (1) · Japan (1) · Russia (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
B. Smith (1) · Denise Yardley, MD (1) · Dennis Slamon, MD (1) · Hoyoung M Maeng, M.D. (1) · John Wrangle (1) · Julie Brahmer, MD (1) · Kartik Konduri, MD (1) · Michael Meyers, MD, PhD (1) · Nilofer Azad (1) · Nilofer Azad, MD (1) · Pasi A Janne, MD, PhD (1) · Robert Raju, MD (1) · Samir Witta, MD (1)
PMID 24583822, PMID 22586682, PMID 23650416, PMID 26577691, PMID 31046743, PMID 33203644, PMID 34453044, PMID 36398439, PMID 37377898, PMID 39532835
U01CA070095 (3), N01CM00038 (2), N01CM00099 (2), P30CA006973 (2), 2004 (1), 2009 (1), 2017 (1), N01CM62205 (1), P01CA247886 (1), P30CA015083 (1), U01CA099168 (1), U10CA021115 (1), U10CA180820 (1), UM1CA186691 (1)